Received Sep 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Z002399 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
no side effects/symptoms; dose 2 on 9/17/2025 and dose 3 on 9/29/2025.; This spontaneous report was received from a nurse regarding a 28-year-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 16-JUL-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 1 dosage form administered as prophylaxis (strength, exact dose, route of administration, anatomical site of injection, lot number, and expiration date were not reported). On 17-SEP-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 1 dosage form administered as prophylaxis (strength, exact dose, route of administration, anatomical site of injection, lot number, and expiration date were not reported). On 29-SEP-2025 (less than 1 month after the second dose), the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 1 dosage form administered as prophylaxis (lot number reported as Z002399, which has been verified as valid, expiration date reported and validated as 20-FEB-2027) (strength, exact dose, route and anatomical site of administration were not reported) (Inappropriate schedule of product administration). No side effects or symptoms were reported in the patient. Additional information is not expected.